findmyKOL
Clinical trialNCT07661420Not, yet, recruitingPhase 1Interventional

211At-MABG in Adults With Advanced Neuroendocrine Cancers

SponsorUniversity of PennsylvaniaEnrollment16Bronchial CarcinoidGastroenteropancreatic Neuroendocrine NeoplasmMedullary Thyroid CancerNeuroendocrine TumorsParagangliomaPheochromocytoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Pennsylvania - Abramson Cancer Center

    Philadelphia, Pennsylvania, United States

    Vivek Narayan, MD, MS

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

1 MBq/k of 211At-MABG Fractionated2 MBq/k1 of 211At-MABG Fractionated4 MBq/k of 211At-MABG Fractionated
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Aug 2026
Primary completion
1 Aug 2029
Completion
1 Aug 2032
Last update posted
22 Jun 2026
Registered enrollment
16
Registry id
NCT07661420
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.